Vitro Biopharma Launches New Products to Advance Breast Cancer Treatment

Golden, Colorado—May 3, 2016 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the launch of breast cancer CAFs (cancer-associated fibroblasts) that provide additional tools for drug discovery in the quest to eradicate cancer. CAFs reside within tumor tissue and serve various functions including suppression of immune responses to cancerous cells, support of tumor cell growth and enhancement of […]

May 4th, 2016|

Vitro Biopharma Announces Early 2016 Results: Increased Revenue and Expansion Activities to Fuel Growth

Golden, Colorado—March 1, 2016 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced increased revenues during its first fiscal quarter 2016 of 143% compared to the same period in 2015, predominately due to further increased sales of its cell lines and MSC-Gro™ Brand of cell culture media products. Vitro Biopharma’s cell line product sales are being driven by […]

March 7th, 2016|

Vitro Biopharma Advances Stem Cell Activation Therapy for Concussion

Golden, Colorado—December 29, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced new developments of its stem cell activation therapy for concussion.  Dr. Omula’s research tying repetitive concussion to chronic traumatic encephalopathy is chronicled in the recently released movie, “Concussion.”  Vitro Biopharma is a leader in the field of stem cell activation therapy now […]

January 12th, 2016|

CEO Letter to Shareholders: 2015 Results Expand Therapy Options for Concussion

Dear Shareholders:

Concussion and traumatic brain injury (TBI) are significant health risks that lack modern therapeutic approaches beyond physical therapy and rehabilitation.  The TBI incidence in the US is 1.5 to 1.7 million new cases per year and is estimated to cost $75 billion per year in the US only.  Concussion is a growing issue within […]

November 5th, 2015|

Vitro Biopharma Launches New Bioanalytical Services and Novel Stem Cell-derived Renal & Neural Cells

Golden, Colorado—September  22, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of its product/service offerings to include biomarker profiling services and stem cell derived neuronal and renal cells. Vitro Biopharma’s new services include simultaneous determination of several molecules through multi-plexed assays.  The cells of our bodies communicate with each other through the […]

September 25th, 2015|

Vitro Biopharma Announces Advancement of its Traumatic Brain Injury Clinical Trial & a Favorable Ruling from the FDA

Golden, Colorado—September 2, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced advances in clinical applications of its products and a favorable ruling by the FDA regarding this trial.  The Company’s phase I clinical trial consists of combining two previously FDA-approved drugs in a novel manner to treat TBI including concussion by regeneration of […]

September 3rd, 2015|

Vitro Biopharma Launches MSC-derived Cardiac and Neural Cells for Pre-clinical Toxicology Testing

Golden, Colorado—June 2, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the commercial launch of cardiac and neural cells that are differentiated from human MSCs.  Our new products include cardiomyocytes, alpha motor neurons and neural stem cells.  In support of this commercial launch, we have also launched an improved and updated website featuring […]

June 8th, 2015|

Vitro Biopharma Expands Capacity to Meet Increased Demand for MSC-Gro™ Stem Cell Culture Media

Golden, Colorado—April 29, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of manufacturing capacity based on a recent orders for bulk quantities of  its MSC-Gro™ Brand of stem cell growth media. Increased demand comes from sales to stem cell researchers and a new customer who recently qualified our media for use in […]

April 29th, 2015|

Vitro Biopharma Announces Advances in Clinical Application of Stem Cell Therapy for Neurological Conditions

Golden, Colorado—February 18, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced advances in its stem cell products and services that enhance opportunities to expand clinical studies of stem therapy of neurological conditions.  We have previously announced a pre-clinical study of our human MSCs for treatment of stroke in animals that showed near reversal […]

February 18th, 2015|

Stem Cell Therapy of Stroke: Current Research Support and Clinical Studies

Adult stem cell therapy is a common FDA-approved procedure for treatment of blood disorders including leukemia, lymphoma and autoimmune diseases.  Cell therapy using other types of adult stem cells including mesenchymal stem cells (MSCs), neural stem cells (NSCs) and muscle stem cells (Satellite cells) is supported by research findings and proof-of-principle clinical trials but this […]

February 17th, 2015|